Key facts
- Luna Diabetes’s last known valuation is $45.5M (Aug 2025).
- It has raised $23.6M; the latest was Later Stage VC ($23.6M) in Aug 2025.
- Notable investors include CONNECT (San Diego), 2468 Ventures, Winklevoss Capital Management, Ascensia Diabetes Care, Interlock Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Luna Diabetes
- ·The full record, as it builds
Funding rounds
No funding rounds for Luna Diabetes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Luna Diabetes
Manufacturer of an automated insulin delivery system designed for overnight use by insulin pen users. The company's platform delivers micro-boluses during sleep without a traditional pump, enabling users to stabilize nighttime glucose, reduce sleep disruptions, and improve daily blood sugar control through a simple, non-intrusive device.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2020
- Employees
- 8
- Website
- lunadiabetes.com/
- Ownership
- Privately Held (backing)
Luna Diabetes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Luna Diabetes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Luna Diabetes in its N-PORT filings yet. We sweep new filings monthly.